Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AN 0128

Drug Profile

AN 0128

Alternative Names: AN-0128; Borinic acid ester - Pfizer; CRM-0005; ONT-0001

Latest Information Update: 29 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anacor Pharmaceuticals
  • Class Antibacterials; Organic boron compounds; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Acne; Atopic dermatitis; Psoriasis; Rosacea; Staphylococcal infections

Most Recent Events

  • 29 Mar 2011 No development reported - Phase-I/II for Psoriasis in USA (Topical)
  • 29 Mar 2011 No development reported - Phase-II for Acne in USA (Topical)
  • 29 Mar 2011 No development reported - Phase-II for Atopic dermatitis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top